|
MED30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.80711001718237E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.23363558152323E-12 |
| Normal-vs-Stage2 |
2.22044604925031E-15 |
| Normal-vs-Stage3 |
4.51860771022439E-14 |
| Normal-vs-Stage4 |
2.41473507855972E-13 |
| Stage1-vs-Stage2 |
3.777800E-03 |
| Stage1-vs-Stage3 |
8.344300E-02 |
| Stage1-vs-Stage4 |
1.978620E-01 |
| Stage2-vs-Stage3 |
1.018610E-01 |
| Stage2-vs-Stage4 |
8.422000E-02 |
| Stage3-vs-Stage4 |
8.048600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.74589248508528E-13 |
| Normal-vs-AfricanAmerican |
5.21209999604366E-08 |
| Normal-vs-Asian |
2.42490472146528E-11 |
| Caucasian-vs-AfricanAmerican |
1.701240E-01 |
| Caucasian-vs-Asian |
6.391000E-01 |
| AfricanAmerican-vs-Asian |
3.417400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.28705943072782E-14 |
| Normal-vs-Female |
2.11675121875032E-12 |
| Male-vs-Female |
1.050240E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.11932726712894E-12 |
| Normal-vs-Age(41-60Yrs) |
1.59983137848485E-13 |
| Normal-vs-Age(61-80Yrs) |
1.62680979798324E-12 |
| Normal-vs-Age(81-100Yrs) |
1.780120E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.387630E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.140490E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.201600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.049800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.553800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.190600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.733800E-02 |
| Classical-VS-Follicular |
1.382340E-02 |
| Classical-VS-Other |
5.822200E-01 |
| Classical-VS-Normal |
7.28939131278139E-12 |
| Tall-VS-Follicular |
9.094200E-01 |
| Tall-VS-Other |
2.477800E-01 |
| Tall-VS-Normal |
1.74205094793933E-12 |
| Follicular-VS-Other |
1.620630E-01 |
| Follicular-VS-Normal |
1.62470037423645E-12 |
| Other-VS-Normal |
1.311630E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.65023550380283E-12 |
| Normal-vs-N1 |
4.3373082903031E-12 |
| N0-vs-N1 |
3.166200E-01 |
|
|
